Long-term efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in patients with type 1 diabetes
Ver / Descargar
Fecha
2017-02-01Autor(es)
Gómez Gómez, Ana MaríaMarín Carrillo, Lisseth Fernanda
Muñoz Velandia, Oscar Mauricio
Rondón Sepúlveda, Martín Alonso
Arévalo Correa, Carol M.
Henao Carrillo, Diana Cristina
Cuervo Díaz, María Camila
Mora Garzón, Edwin Ronald
Autor(es) Corporativo(s)
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Enfermedades Crónicas del Adulto
Tipo
Artículo de revista
ISSN
1520-9156 / 1557-8593 (Electrónico)
Páginas
109-114
Tipo de artículo
Artículo original
Compartir este registro
Citación
Documentos PDF
Abstract
BACKGROUND:
Literature supports short-term efficacy and safety of Sensor Augmented Insulin Pump (SAP) therapy in patients with type 1 diabetes (T1D). However, no data are available showing long-term outcomes. Our study describes the long-term outcomes of SAP therapy with low-glucose suspend feature (SAP+LGS) in hypoglycemia in a Colombian population with T1D and hypoglycemia.
METHODS:
A cohort study was conducted with T1D patients receiving SAP+LGS therapy who initiated this therapy because of hypoglycemia at San Ignacio University Hospital diabetes center in Bogotá, Colombia. Glycated hemoglobin (A1c) was assessed at least every 6 months, severe hypoglycemia (SH) and hypoglycemia unawareness (HU) incidence yearly. Adherence to therapy was also evaluated.
RESULTS:
One hundred eleven patients were included in the analysis. Total daily insulin dose was reduced during follow-up (mean difference -0.22 U/kg; 95% confidence interval [CI] -0.18 to -0.26; P < 0.001). A1c levels were reduced from a baseline value of 8.8% ± 1.9% to 7.5% ± 1.0% at 5 months (mean difference -1.3%; 95% CI -1.09 to -1.50; P < 0.001) and 7.1% ± 0.8% (mean difference -1.7%; 95% CI -1.59 to -1.90; P < 0.001) at the end of follow-up (47 months on average). The incidence of SH and HU episodes decreased significantly since the first year, and this effect was maintained over time (P < 0.001).
CONCLUSIONS:
SAP+LGS therapy in T1D patients with hypoglycemia led to a significant and sustained decrease in A1c during long periods of follow-up, as well as a significant reduction in SH and HU. Future randomized clinical trials are desired.
Keywords
Continuous glucose monitoringContinuous subcutaneous insulin infusion
Hypoglycemia unawareness
Long-term follow-up
Low-glucose suspend function
Sensor augmented insulin pump therapy
Severe hypoglycemia
Type 1 diabetes
Cobertura espacial (Ciudades)
Bogotá (Colombia)Cobertura espacial
ColombiaEnlace al recurso
https://www.liebertpub.com/doi/abs/10.1089/dia.2016.0332?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=diaFuente
Diabetes Technology & Therapeutics; Vol. 19 Núm. 2 (2017)
Estadísticas Google Analytics